-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shisi Pharmaceutical: Accelerating Production of Arbidol Capsules to Meet Frontline Demand for Epidemic Prevention and Control
Category:
发布时间：2020-02-06
【概要描述】
“Since the outbreak began, we have received successive requests from clinical medical institutions in Hubei, Jiangxi, Beijing, and other regions for additional supplies of arbidol hydrochloride capsules,” said Han Shuqin, Deputy General Manager in charge of production at Shijiazhuang Sihua Pharmaceutical Co., Ltd., on February 5. She added that the arbidol capsule production line in the oral dosage-form workshop is now operating around the clock in two shifts, with all employees working without leave to fully support the frontline demand for epidemic-control medications.
“Since the outbreak began, we have received successive requests from clinical medical institutions in Hubei, Jiangxi, Beijing, and other regions for additional supplies of abidor hydrochloride capsules,” said Han Shuqin, Deputy General Manager in charge of production at Shijiazhuang Sihua Pharmaceutical Co., Ltd., on February 5. She added that the oral dosage-form workshop’s abidor capsule production line is now operating around the clock in two shifts, with all employees working without leave to fully support the urgent demand for medications on the front lines of epidemic prevention and control. From mid-January 2020 to the present, Shijiazhuang Sihua has cumulatively shipped 1.36 million abidor hydrochloride capsules to Hubei Province, including 960,000 units destined for Wuhan.
In recent days, the oral dosage-form workshop at Shijiazhuang Sihua Pharmaceutical Co., Ltd. has been operating at full capacity on the abidor hydrochloride capsule production line. Currently, daily output has reached 900,000 capsules, nearly doubling the usual level. With the gradual resumption of supply of the key raw material, abidor, production capacity for abidor capsules is expected to increase further, thereby easing the current tight supply situation in the market.
Sun Lijie, Director of the Shijiazhuang Fourth Pharmaceutical Research Institute, stated that Arbidol is primarily used to treat upper respiratory tract infections caused by influenza A and B viruses, among others. It works by inhibiting the fusion of the viral envelope with host cell membranes, thereby blocking the initial step of viral infection. In 2019, it was first included in the National Medical Insurance Catalogue and has since been repeatedly listed as a clinically recommended antiviral agent for influenza in the guidelines issued by the National Health Commission.
According to the Hebei Provincial Drug Administration, in response to epidemic prevention and control needs and given that Shijiazhuang Sihua Pharmaceutical Co., Ltd.’s abidor hydrochloride capsules have experienced production constraints due to insufficient supply of the active pharmaceutical ingredient, the Administration convened a special meeting bringing together drug regulatory officials, drug registration personnel, technical review experts, and pharmaceutical testing specialists. The meeting aimed to help the company develop and implement solutions, with a dedicated member of the emergency approval team assigned to coordinate closely with the company. Meanwhile, the Chemical Drug Regulatory Division dispatched personnel directly to the enterprise to provide on-site technical assistance and guidance on relevant policies and regulations. On the afternoon of January 28, following receipt of the test report from the Hebei Provincial Institute for Drug Control, the Provincial Drug Administration promptly approved Shijiazhuang Sihua Pharmaceutical Co., Ltd.’s application to add an additional API supplier. With this approval, the daily production capacity of abidor hydrochloride capsules at Shijiazhuang Sihua can now reach 1 million units, thereby effectively ensuring the supply of antiviral medications for clinical use.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091